The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.q

Pericarditis (see also under XIIc)

Publications

Conte C, Princi G, D'Amario D, Sanna T, Pedicino D, Liuzzo G

Incessant pericarditis following the second dose of SARS-CoV-2 mRNA vaccine successfully treated with anakinra: a case report.

European heart journal. Case reports. 2022;6(9):ytac357

Singh A, Nguyen L, Everest S, Afzal S, Shim A

Acute Pericarditis Post mRNA-1273 COVID Vaccine Booster.

Cureus. 2022;14(2):e22148

Vidula MK, Ambrose M, Glassberg H, Chokshi N, Chen T, Ferrari VA, Han Y

Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines.

Cureus. 2021;13(6):e15576

Wise J

Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines?

BMJ (Clinical research ed.). 2021;373:n1635

Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, Broyde A, Polachek A, Wollman J, Litinsky I, Meridor K, Nochomovitz H, Silberman A, Rosenberg D, Feld J, Haddad A, Gazzit T, Elias M, Higazi N, Kharo

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.

Annals of the rheumatic diseases. 2021;80(10):1330-1338